Relapsing MS: weighing AHSCT against staying on DMTs
This is a composite decision situation, not a real patient, testimonial or individual treatment recommendation.
You have relapsing-remitting multiple sclerosis, you have cycled through one or two disease-modifying therapies, and relapses still break through. A forum thread or a clinic page introduced AHSCT — “resetting the immune system” — and now you are trying to work out whether it is a real option or a desperate one.
This profile is different from most on this site in one important way: AHSCT is not fringe. It is an intensive, established haematology procedure with genuine trial evidence in the right patients — and genuine risks.
What the data says for this situation
Our snapshot counts 38 haematopoietic transplant studies and 37 MSC studies for MS — a rare near-tie that reflects two completely different approaches. AHSCT (chemotherapy followed by your own blood stem cells) has randomised and long-term cohort evidence showing strong suppression of relapses in active relapsing disease that failed high-efficacy drugs; professional consensus now positions it exactly there. It does little for later progressive disease without inflammatory activity. MSC infusions, by contrast, remain experimental with modest, unconfirmed signals.
The decision is genuinely medical: transplant-related mortality is low in experienced centres but not zero, and fertility, infection and early-menopause consequences are real. A clinic that offers AHSCT to progressive MS without inflammatory activity — or blurs MSC drips into the same sales page — is selling past the evidence.
Questions worth asking any provider
- Does my disease profile (relapses, MRI activity, DMT history) match the groups where AHSCT showed benefit?
- What is this centre’s transplant-related mortality and how many MS transplants has it done?
- What happens to my existing DMT options if AHSCT fails?
- Fertility preservation: what, when, covered by whom?
Red flags specific to this situation
- AHSCT marketed for progressive MS without inflammatory activity
- MSC infusions sold under the AHSCT evidence umbrella
- No haematology team or ICU on site
Cost context
AHSCT abroad is typically quoted €40,000–€80,000 including conditioning and aftercare; MSC infusion packages are cheaper and evidentially much weaker. Country figures with dates are in the cost index.
FAQ
Is AHSCT a cure for MS?
No, but in active relapsing MS that failed strong drugs it produces some of the longest relapse-free intervals recorded in trials.
Is the MSC drip a lighter version of AHSCT?
No. They share the word “stem” and nothing else — different cells, different mechanism, different evidence tier.
→ Build questions for a specific provider · → Cost calculator
Interactive/editorial page by the StemCellAtlas research team. Where registry or literature counts appear, they use the dated 2026-08-29 snapshot. Browser-only tools do not send or store answers. Page generated 2026-08-29. See our editorial standards.